One Molecule, Two Fates: Metadichol Co-Activates Pluripotency and Cardiac Gene Networks in Human Cardiac Fibroblasts
Medical Research Archives · 30.09.2026 · 14 (9)
DOI: 10.18103/mra.2026.0490 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 30.09.2026. Verfasst von P. R Raghavan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardiovascular disease remains the leading cause of global mortality, with myocardial fibrosis representing a critical barrier to cardiac regeneration. Human cardiac fibroblasts constitute the predominant non-myocyte population in the heart and are principal mediators of pathological fibrosis following injury. Their direct reprogramming toward cardiac progenitor or cardiomyocyte-like phenotypes is of substantial therapeutic interest. Metadichol, a nanoemulsion of long-chain C26–C30 plant-derived aliphatic alcohols, has previously demonstrated pleiotropic biological activities including modulation of nuclear receptors, induction of Yamanaka reprogramming factors, and activation of anti-aging pathways across multiple human cell types. This study presents new quantitative reverse-transcription polymerase chain reaction data characterizing the dose-dependent effects of Metadichol on thirteen cardiac progenitor, pluripotency, and anti-aging genes in human cardiac fibroblasts, and integrates these findings with published data from normal human dermal fibroblasts and human embryonic stem cells.
Methods
Human cardiac fibroblasts were treated with Metadichol at 1 pg/mL, 100 pg/mL, 1 ng/mL, and 100 ng/mL for 24 hours. Gene expression was quantified by SYBR Green quantitative reverse-transcription polymerase chain reaction (Bio-Rad CFX Maestro) using beta-actin as reference, applying the 2^(−ΔΔCt) method. Thirteen target genes were assessed: OCT-4, NANOG, and SOX2 (pluripotency); c-Kit, GATA4, NKX2.5, ISL1, MEF2C, TBX5, MESP1, and WT1 (cardiac progenitor); and TERT and ESRRG (anti-aging and nuclear receptor).
Results
Metadichol treatment induced robust, dose-dependent upregulation with peak induction at 1 ng/mL: c-Kit (12.23-fold), GATA4 (11.51-fold), NKX2.5 (11.48-fold), OCT-4 (10.36-fold), SOX2 (10.21-fold), NANOG (5.86-fold), TERT (4.47-fold), and ESRRG (3.76-fold). TBX5 and MESP1 were selectively downregulated at all doses (0.08- and 0.01-fold minimum, respectively). Correlation analysis revealed strong co-regulation within two gene clusters: pluripotency factors (OCT-4, SOX2, and NANOG; r > 0.95) and cardiac transcription factors (GATA4, NKX2.5, and c-Kit; r > 0.90). The optimal dose in human cardiac fibroblasts (1 ng/mL) differed from that in normal human dermal fibroblasts (100 pg/mL), reflecting cell-type-specific transcriptional thresholds (see Figures 1–4).
Conclusions
Metadichol simultaneously activates pluripotency and cardiac identity gene networks in human cardiac fibroblasts without viral vectors or genetic modification, positioning it as a novel small-molecule cardiac reprogramming agent.
Zitieren
APA
Raghavan, P. R. (2026). One Molecule, Two Fates: Metadichol Co-Activates Pluripotency and Cardiac Gene Networks in Human Cardiac Fibroblasts. Medical Research Archives, 14(9). https://doi.org/10.18103/mra.2026.0490
Vancouver
Raghavan PR. One Molecule, Two Fates: Metadichol Co-Activates Pluripotency and Cardiac Gene Networks in Human Cardiac Fibroblasts. Medical Research Archives. 2026;14(9). doi:10.18103/mra.2026.0490
BibTeX
@article{Raghavan2026,
author = {Raghavan, P. R},
title = {One Molecule, Two Fates: Metadichol Co-Activates Pluripotency and Cardiac Gene Networks in Human Cardiac Fibroblasts},
journal = {Medical Research Archives},
year = {2026},
volume = {14},
number = {9},
doi = {10.18103/mra.2026.0490}
}
EUVIMED